Tirbanibulin

What Is Tirbanibulin?[edit | edit source]

Tirbanibulin (KLISYRI) is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp.

Tirbanibulin (KLISYRI) is indicated for the topical treatment of actinic keratosis on the face or scalp.

Tirbanibulin is a microtubule inhibitor.
The mechanism of action of KLISYRI for the topical treatment of actinic keratosis is unknown.
An orally bioavailable small molecule Src kinase inhibitor with potential antineoplastic activity.
Unlike other Src kinase inhibitors which bind to the ATP-binding site, tirbanibulin specifically binds to the peptide substrate binding site of Src kinase; inhibition of kinase activity may result in the inhibition of primary tumor growth and the suppression of metastasis.
Src tyrosine kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation and metastasis.

For topical use only; not for oral or ophthalmic use.
Apply sufficient amount of KLISYRI to evenly cover up to 25 cm2 treatment field on the face or scalp once daily for 5 consecutive days using 1 single-dose packet per application.
Wash hands immediately with soap and water after application.
Avoid washing and touching the treated area for approximately 8 hours after application of KLISYRI.
Following this time, the area may be washed with a mild soap.
Avoid transfer of KLISYRI to the periocular area.
Avoid application near and around the mouth and lips.

This medicine is available in fallowing doasage form:

As an ointment: 1% white to off-white ointment in a single-dose packet (2.5 mg tirbanibulin in 250 mg).

This medicine is available in fallowing brand namesː

Common possible side effects of this medicine include:

Avoid transfer of the drug into the eyes and to the periocular area during and after application.
Wash hands immediately after application.
If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.
Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation and erosion/ulceration) in the treated area can occur after topical application of KLISYRI.
Avoid use until skin is healed from any previous drug, procedure, or surgical treatment.

Overdose of this medicine could cause an increase in incidence and severity of local skin reactions.

There are no available data with KLISYRI use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.

It is not known if KLISYRI is safe and effective in children less than 18 years of age.

Need help finding a doctor or specialist anywhere in the world? WikiMD's DocFinder can help with millions of doctors!

This article is a stub. Help WikiMD grow by registering to expand it. Editing is available only to registered and verified users. About WikiMD: A comprehensive, free health & wellness encyclopedia.

This dermatologic drug article is a stub. You can help WikiMD by expanding it.

‎

Tirbanibulin Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.